Researchers at Indiana University School of Medicine have made a breakthrough in Type 1 diabetes treatment with a new “smart insulin” that combines insulin and glucagon into one molecule. This lab-designed protein has shown promise in reducing hypoglycemia bouts in rat studies. The protein works by mimicking the body’s natural response to insulin and glucagon, signaling the liver to adjust blood sugar levels accordingly. This could lead to a new treatment avenue for people with Type 1 diabetes, potentially simplifying the management of blood sugar levels and reducing the risk of hypoglycemia. The researchers aim to develop two types of “smart insulin”: a long-acting version for weekly injections and a short-acting version for use in insulin pumps. While the results are promising, further development is needed before the treatment can be cleared for public use.